Less than 1% of patients receiving Euflexxa® experienced effusion compared with 8.1% of patients receiving Synvisc® (P=.0015)2
One effusion in a patient receiving Euflexxa® versus 15 effusions in 13 patients receiving Synvisc®
Reference: 1.Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthr Cartil. 2006;14:154-162. 2. Data on file. Bio-Technology General (Israel) Ltd-BTG.